Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IRONWOOD PHARMACEUTICALS, INC.

(IRWD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/12/2021 10/13/2021 10/14/2021 10/15/2021 10/18/2021 Date
13.85(c) 13.55(c) 13.65(c) 13.66(c) 13.41 Last
733 297 1 584 538 1 045 501 1 815 860 1 503 272 Volume
+0.58% -2.17% +0.74% +0.07% -1.83% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 408 M - -
Net income 2021 445 M - -
Net cash position 2021 143 M - -
P/E ratio 2021 5,29x
Yield 2021 -
Sales 2022 444 M - -
Net income 2022 228 M - -
Net cash position 2022 351 M - -
P/E ratio 2022 9,38x
Yield 2022 -
Capitalization 2 184 M 2 184 M -
EV / Sales 2021 5,00x
EV / Sales 2022 4,13x
Nbr of Employees 232
Free-Float 98,6%
More Financials
Company
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company. The Company is focused on the development and commercialization of GI product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult... 
More about the company
Ratings of Ironwood Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about IRONWOOD PHARMACEUTICALS, INC.
10/12IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals..
MT
09/02IRONWOOD PHARMACEUTICALS : to Participate in Upcoming September Investor Conferences
BU
08/26IRONWOOD PHARMACEUTICALS : Gets FDA Approval for Revised Linzess Label
MT
08/26IRONWOOD PHARMACEUTICALS : Announces FDA Approval of Revised LINZESS® (linaclotide) Label
BU
08/26Ironwood Pharmaceuticals Announces FDA Approval of Revised Linzess® (Linaclotide) Label
CI
08/05IRONWOOD PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and..
AQ
08/05Tranche Update on Ironwood Pharmaceuticals, Inc.'s Equity Buyback Plan announced on May..
CI
08/05IRONWOOD PHARMACEUTICALS : Pharma Q2 Profit, Revenue Rise; Boosts Full-Year Guidance
MT
08/05IRONWOOD : Q2 Earnings Snapshot
AQ
08/05IRONWOOD PHARMACEUTICALS : Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q2 Reven..
MT
08/05IRONWOOD PHARMACEUTICALS : Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Posts Q2 EPS $0...
MT
08/05IRONWOOD PHARMACEUTICALS INC : Results of Operations and Financial Condition, Financial St..
AQ
08/05Ironwood Pharmaceuticals, Inc. Updates Earnings Guidance for 2021
CI
08/05IRONWOOD PHARMACEUTICALS : Reports Strong Second-Quarter 2021 Results, Raises Full-Year Gu..
BU
08/05Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended Ju..
CI
More news
News in other languages on IRONWOOD PHARMACEUTICALS, INC.
2016La chute des biotechs pourrait favoriser les fusions-acquisitions
More news
Analyst Recommendations on IRONWOOD PHARMACEUTICALS, INC.
More recommendations
Chart IRONWOOD PHARMACEUTICALS, INC.
Duration : Period :
Ironwood Pharmaceuticals, Inc. Technical Analysis Chart | IRWD | US46333X1081 | MarketScreener
Technical analysis trends IRONWOOD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 13,41 $
Average target price 12,80 $
Spread / Average Target -4,55%
EPS Revisions
Managers and Directors
Thomas A. McCourt President, Chief Executive Officer & Director
Jason Rickard Chief Financial Officer
Julie Harris McHugh Executive Chairman
Michael Shetzline Chief Medical Officer & Senior Vice President
Cristina Almansa Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
IRONWOOD PHARMACEUTICALS, INC.19.93%2 225
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-39.69%25 414